WO2000059902A3 - Aryl sulfonyls as factor xa inhibitors - Google Patents

Aryl sulfonyls as factor xa inhibitors Download PDF

Info

Publication number
WO2000059902A3
WO2000059902A3 PCT/US2000/008364 US0008364W WO0059902A3 WO 2000059902 A3 WO2000059902 A3 WO 2000059902A3 US 0008364 W US0008364 W US 0008364W WO 0059902 A3 WO0059902 A3 WO 0059902A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitors
factor
aryl sulfonyls
sulfonyls
aryl
Prior art date
Application number
PCT/US2000/008364
Other languages
French (fr)
Other versions
WO2000059902A2 (en
Inventor
Ruth R Wexler
Irina C Jacobson
Original Assignee
Du Pont Pharm Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont Pharm Co filed Critical Du Pont Pharm Co
Priority to DE60003025T priority Critical patent/DE60003025T2/en
Priority to EP00923096A priority patent/EP1175419B1/en
Priority to AU43276/00A priority patent/AU4327600A/en
Priority to AT00923096T priority patent/ATE241621T1/en
Priority to CA002368630A priority patent/CA2368630A1/en
Publication of WO2000059902A2 publication Critical patent/WO2000059902A2/en
Publication of WO2000059902A3 publication Critical patent/WO2000059902A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

The present application describes aryl sulfonyls of formula (I) or pharmaceutically acceptable salt or prodrug forms thereof, wherein D, E, and M are defined below, are effective factor Xa inhibitors.
PCT/US2000/008364 1999-04-02 2000-03-30 Aryl sulfonyls as factor xa inhibitors WO2000059902A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
DE60003025T DE60003025T2 (en) 1999-04-02 2000-03-30 ARYLSULFONYLE AS FACTOR XA INHIBITORS
EP00923096A EP1175419B1 (en) 1999-04-02 2000-03-30 Aryl sulfonyls as factor xa inhibitors
AU43276/00A AU4327600A (en) 1999-04-02 2000-03-30 Aryl sulfonyls as factor xa inhibitors
AT00923096T ATE241621T1 (en) 1999-04-02 2000-03-30 ARYLSULFONYLS AS FACTOR XA INHIBITORS
CA002368630A CA2368630A1 (en) 1999-04-02 2000-03-30 Aryl sulfonyls as factor xa inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12763499P 1999-04-02 1999-04-02
US60/127,634 1999-04-02

Publications (2)

Publication Number Publication Date
WO2000059902A2 WO2000059902A2 (en) 2000-10-12
WO2000059902A3 true WO2000059902A3 (en) 2001-04-26

Family

ID=22431091

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/008364 WO2000059902A2 (en) 1999-04-02 2000-03-30 Aryl sulfonyls as factor xa inhibitors

Country Status (8)

Country Link
US (2) US6399644B1 (en)
EP (1) EP1175419B1 (en)
AT (1) ATE241621T1 (en)
AU (1) AU4327600A (en)
CA (1) CA2368630A1 (en)
DE (1) DE60003025T2 (en)
ES (1) ES2197092T3 (en)
WO (1) WO2000059902A2 (en)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6339099B1 (en) * 1997-06-20 2002-01-15 Dupont Pharmaceuticals Company Guanidine mimics as factor Xa inhibitors
JP2004501913A (en) * 2000-06-23 2004-01-22 ブリストル−マイヤーズ　スクイブ　ファーマ　カンパニー Heteroaryl-phenyl substituted factor Xa inhibitors
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
SI1427415T1 (en) 2001-09-21 2009-12-31 Bristol Myers Squibb Co Lactam-containing compounds and derivatives thereof as factor xa inhibitors
TWI320039B (en) 2001-09-21 2010-02-01 Lactam-containing compounds and derivatives thereof as factor xa inhibitors
AU2002350217A1 (en) 2001-12-04 2003-06-17 Bristol-Myers Squibb Company Glycinamides as factor xa inhibitors
TW200302225A (en) 2001-12-04 2003-08-01 Bristol Myers Squibb Co Substituted amino methyl factor Xa inhibitors
AR039241A1 (en) * 2002-04-04 2005-02-16 Biogen Inc HETEROARILOS TRISUSTITUIDOS AND METHODS FOR ITS PRODUCTION AND USE OF THE SAME
BR0309551A (en) 2002-04-26 2005-02-09 Upjohn Co Substituted Pyrazine Derivatives
EP1505966A4 (en) 2002-05-10 2006-08-30 Bristol Myers Squibb Co 1,1-disubstituted cycloalkyl derivatives as factor xa inhibitors
CA2494421A1 (en) 2002-08-06 2004-02-12 Astrazeneca Ab Condensed pyridines and pyrimidines with tie2 (tek) activity
UA80295C2 (en) * 2002-09-06 2007-09-10 Biogen Inc Pyrazolopyridines and using the same
US7319109B2 (en) 2002-11-22 2008-01-15 Smith Kline Beecham Corporation Farnesoid X receptor agonists
SI1569912T1 (en) 2002-12-03 2015-09-30 Pharmacyclics Llc 2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors
US7098231B2 (en) * 2003-01-22 2006-08-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7223785B2 (en) * 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7122557B2 (en) 2003-03-18 2006-10-17 Bristol-Myers Squibb Company Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors
US7592352B2 (en) 2003-05-06 2009-09-22 Smithkline Beecham Corporation Substituted thieno and furo-pyridines
TWI372050B (en) 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
PL1651612T3 (en) 2003-07-22 2012-09-28 Astex Therapeutics Ltd 3,4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators
UA94602C2 (en) * 2004-02-20 2011-05-25 Берингер Ингельхайм Интернациональ Гмбх Viral polymerase inhibitors
CN1938021A (en) * 2004-03-08 2007-03-28 惠氏公司 Ion channel modulators
US8110573B2 (en) 2004-12-30 2012-02-07 Astex Therapeutics Limited Pyrazole compounds that modulate the activity of CDK, GSK and aurora kinases
AR054425A1 (en) 2005-01-21 2007-06-27 Astex Therapeutics Ltd PIPERIDIN ADDITION SALTS 4-IL-ACID AMID 4- (2,6-DICLORO-BENZOILAMINO) 1H-PIRAZOL-3-CARBOXILICO.
MX2007008781A (en) 2005-01-21 2007-09-11 Astex Therapeutics Ltd Pharmaceutical compounds.
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
JP5015154B2 (en) * 2005-08-12 2012-08-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Viral polymerase inhibitor
US7781460B2 (en) 2005-09-05 2010-08-24 Ranbaxy Laboratories Limited Substituted indazoles as inhibitors of phosphodiesterase type-IV
US20100022571A1 (en) 2005-09-16 2010-01-28 Palle Venkata P Substituted pyrazolo [3,4-b]pyridines as phosphodiesterase inhibitors
US7915286B2 (en) 2005-09-16 2011-03-29 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
US8399442B2 (en) 2005-12-30 2013-03-19 Astex Therapeutics Limited Pharmaceutical compounds
JP5523829B2 (en) 2006-06-29 2014-06-18 アステックス、セラピューティックス、リミテッド Compound drug
DK2124944T3 (en) 2007-03-14 2012-04-23 Ranbaxy Lab Ltd Pyrazolo [3,4-b] pyridine derivatives as phosphodiesterase inhibitors
BRPI0910656A2 (en) 2008-04-16 2019-09-24 Karobio Ab "Estrogen receptor binding compounds, their use and pharmaceutical composition"
AR072297A1 (en) 2008-06-27 2010-08-18 Novartis Ag DERIVATIVES OF INDOL-2-IL-PIRIDIN-3-ILO, PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM AND ITS USE IN MEDICINES FOR THE TREATMENT OF DISEASES MEDIATED BY THE SYNTHESIS ALDOSTERONE.
WO2010068775A2 (en) 2008-12-11 2010-06-17 Amira Pharmaceuticals, Inc. Alkyne antagonists of lysophosphatidic acid receptors
GB2466121B (en) 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors
GB2470833B (en) 2009-06-03 2011-06-01 Amira Pharmaceuticals Inc Polycyclic antagonists of lysophosphatidic acid receptors
EP2462128B1 (en) 2009-08-04 2016-09-21 Amira Pharmaceuticals, Inc. Compounds as lysophosphatidic acid receptor antagonists
GB2474748B (en) 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
GB2474120B (en) 2009-10-01 2011-12-21 Amira Pharmaceuticals Inc Compounds as Lysophosphatidic acid receptor antagonists
CN103596947A (en) 2011-04-05 2014-02-19 艾米拉医药股份有限公司 3- or 5 - bi phenyl - 4 - ylisoxazole - based compounds useful for the treatment of fibrosis, pain, cancer and respiratory, allergic, nervous system or cardiovascular disorders
GB201113538D0 (en) 2011-08-04 2011-09-21 Karobio Ab Novel estrogen receptor ligands
CA3164693A1 (en) * 2014-03-07 2015-09-11 Biocryst Pharmaceuticals, Inc. Human plasma kallikrein inhibitors
CA3013958A1 (en) * 2016-02-11 2017-08-17 Bayer Cropscience Aktiengesellschaft Substituted -oxyimidazolyl-carboxamides as pest control agents
CN113365617A (en) * 2018-10-16 2021-09-07 乔治亚州立大学研究基金会股份有限公司 Carbon monoxide prodrugs for the treatment of medical conditions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998057951A1 (en) * 1997-06-19 1998-12-23 Du Pont Pharmaceuticals Company NOVEL GUANIDINE MIMICS AS FACTOR Xa INHIBITORS
WO1998057937A2 (en) * 1997-06-19 1998-12-23 The Du Pont Merck Pharmaceutical Company Inhibitors of factor xa with a neutral p1 specificity group

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3633840A1 (en) 1986-10-04 1988-04-14 Hoechst Ag PHENYLPYRAZOLIC CARBONIC ACID DERIVATIVES, THEIR PRODUCTION AND USE AS PLANT GROWTH REGULATORS AND SAFENERS
CA2396738C (en) 1990-11-30 2006-08-29 Masatoshi Chihiro Thiazole derivatives as active superoxide radical inhibitors
DE4124942A1 (en) 1991-07-27 1993-01-28 Thomae Gmbh Dr K 5-LOW HETEROCYCLES, METHOD FOR THE PRODUCTION THEREOF AND MEDICAMENTS CONTAINING SUCH COMPOUNDS
WO1994024095A1 (en) 1993-04-16 1994-10-27 Abbott Laboratories Immunosuppressive agents
US5849736A (en) 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
WO1995014683A1 (en) 1993-11-24 1995-06-01 The Du Pont Merck Pharmaceutical Company Novel isoxazoline and isoxazole fibrinogen receptor antagonists
US5563158A (en) 1993-12-28 1996-10-08 The Dupont Merck Pharmaceutical Company Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists
US5658909A (en) 1994-11-17 1997-08-19 Molecular Geriatrics Corporation Certain substituted 1-aryl-3-piperazin-1'-yl propanones to treat Alzheimer's Disease
US5750550A (en) * 1995-09-15 1998-05-12 Sanofi 2-(pyrazol-5-yl-oxymethyl)-1,2-benzisothiazol-3 (2H)-One 1, 1-dioxides and compositions and method of use thereof
WO1997032583A1 (en) 1996-03-08 1997-09-12 Smithkline Beecham Corporation Use of csaidtm compounds as inhibitors of angiogenesis
WO1997047299A1 (en) 1996-06-12 1997-12-18 3-Dimensional Pharmaceuticals, Inc. Amidino and guanidino heterocyclic protease inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998057951A1 (en) * 1997-06-19 1998-12-23 Du Pont Pharmaceuticals Company NOVEL GUANIDINE MIMICS AS FACTOR Xa INHIBITORS
WO1998057937A2 (en) * 1997-06-19 1998-12-23 The Du Pont Merck Pharmaceutical Company Inhibitors of factor xa with a neutral p1 specificity group

Also Published As

Publication number Publication date
EP1175419A2 (en) 2002-01-30
CA2368630A1 (en) 2000-10-12
EP1175419B1 (en) 2003-05-28
US6689770B2 (en) 2004-02-10
AU4327600A (en) 2000-10-23
ATE241621T1 (en) 2003-06-15
US6399644B1 (en) 2002-06-04
ES2197092T3 (en) 2004-01-01
WO2000059902A2 (en) 2000-10-12
DE60003025T2 (en) 2004-03-18
US20030050315A1 (en) 2003-03-13
DE60003025D1 (en) 2003-07-03

Similar Documents

Publication Publication Date Title
WO2000059902A3 (en) Aryl sulfonyls as factor xa inhibitors
WO2003048081A3 (en) Glycinamides as factor xa inhibitors
WO2004037176A3 (en) Quinazolinones and derivatives thereof as factor xa inhibitors
WO2003047520A3 (en) SUBSTITUTED AMINO METHYL FACTOR Xa INHIBITORS
CA2349330A1 (en) Nitrogen containing heterobicycles as factor xa inhibitors
ZA200306490B (en) Inhibitors of factor Xa.
JO2311B1 (en) Alkyne-aryl phosphodiesterase-4 inhibitors
WO2001019829A3 (en) Pyrazolopyrimidines as therapeutic agents
WO2005032472A3 (en) Pyrrolidine and piperidine derivatives as factor xa inhibitors
AU6762400A (en) Inhibitors of factor xa
AU5723500A (en) Inhibitors of factor xa
AU5158100A (en) Inhibitors of factor xa
AU5283900A (en) Inhibitors of factor xa
AU3857300A (en) Inhibitors of factor xa
WO2006047528A3 (en) Pyrazolobenzamides and derivatives as factor xa inhibitors
WO2001030781A3 (en) INHIBITORS OF αLβ2 MEDIATED CELL ADHESION
AU4064597A (en) Amidinophenyl-pyrrolidines, -pyrrolines, and -isoxazolidines and derivatives thereof
WO2004031145A3 (en) Lactam-containing diaminoalkyl, beta-aminoacids, alpha-aminoacids and derivatives thereof as factor xa inhibitors
AU5283600A (en) Inhibitors of factor xa
WO2002016312A3 (en) NOVEL COMPOUNDS INHIBITING FACTOR Xa ACTIVITY
WO2003053971A8 (en) Pyridoquinoxaline antivirals
WO2001081316A3 (en) Substituted phenyl farnesyltransferase inhibitors
WO2004048381A3 (en) Pyrazoloazepine compounds as pharmaceutical agents
WO2001046128A3 (en) Tryptase inhibitors
WO2001010848A3 (en) Diazocin-dione derivatives and their use s tryptase inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BR CA CN CZ EE HU IL IN JP KR LT LV MX NO NZ PL RO SG SI SK TR UA VN ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU BR CA CN CZ EE HU IL IN JP KR LT LV MX NO NZ PL RO SG SI SK TR UA VN ZA

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

ENP Entry into the national phase

Ref document number: 2368630

Country of ref document: CA

Ref country code: CA

Ref document number: 2368630

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000923096

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000923096

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2000923096

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP